文献速递慢阻肺呼吸道感染

慢阻肺痰液微生物组分析:超越单一病原体检测

Sputum microbiome profiling in COPD: beyond singular pathogen detection.
PubMed 文献 · Thorax · 2020-01-29

本综述指出,不依赖培养的微生物测序技术揭示呼吸道存在传统培养无法检测的复杂微生物组;痰液是慢阻肺微生物组研究的优选样本,微生物群落结构与多样性与疾病严重程度和临床结局相关,但现有证据主要来自横断面16S rRNA基因测序研究,需标准化纵向研究及全宏基因组/宏转录组和代谢组学进一步探索。

要点

  • 痰液微生物组群落结构与多样性与慢阻肺严重程度及临床结局相关。
  • 现有证据多为横断面16S rRNA基因测序研究,需标准化纵向研究。
  • 微生物组研究正转向全宏基因组、宏转录组和代谢组学以回答功能问题。

核心结论

  • 痰液微生物组群落结构与多样性与慢阻肺疾病严重程度和临床结局相关,但证据仍处于早期阶段。

研究设计与样本

  • 综述,总结高通量微生物组测序技术原理及慢阻肺痰液微生物组研究现状。

主要发现

  • 不依赖培养的测序技术发现呼吸道存在传统培养无法检测的复杂微生物组。
  • 痰液是易获取样本,为慢阻肺病理生物学提供大量信息,是微生物组研究优选样本类型。
  • 痰液微生物组可能仅部分反映呼吸道微生物组。
  • 越来越多证据表明微生物群落结构与多样性与慢阻肺严重程度和临床结局相关,稳定期和急性加重期均如此。
  • 当前证据主要限于使用16S rRNA基因测序的横断面研究,试图回答「谁在那里」。

临床怎么用

  • 痰液微生物组分析有望成为慢阻肺临床生物标志物,但尚处于研究阶段。
  • 需采用标准化方案的纵向研究以回答痰液采样技术差异等未解问题。
  • 全基因组和代谢组学可回答「它们能做什么」和「它们正在做什么」。

局限性

  • 现有证据主要来自横断面研究,难以推断因果和纵向变化。
  • 痰液微生物组可能仅部分反映呼吸道微生物组。
  • 全宏基因组和代谢组学技术难度更高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Culture-independent microbial sequencing techniques have revealed that the respiratory tract harbours a complex microbiome not detectable by conventional culturing methods. The contribution of the microbiome to chronic obstructive pulmonary disease (COPD) pathobiology and the potential for microbiome-based clinical biomarkers in COPD are still in the early phases of investigation. Sputum is an easily obtainable sample and has provided a wealth of information on COPD pathobiology, and thus has been a preferred sample type for microbiome studies. Although the sputum microbiome likely reflects the respiratory microbiome only in part, there is increasing evidence that microbial community structure and diversity are associated with disease severity and clinical outcomes, both in stable COPD and during the exacerbations. Current evidence has been limited to mainly cross-sectional studies using 16S rRNA gene sequencing, attempting to answer the question 'who is there?' Longitudinal studies using standardised protocols are needed to answer outstanding questions including differences between sputum sampling techniques. Further, with advancing technologies, microbiome studies are shifting beyond the examination of the 16S rRNA gene, to include whole metagenome and metatranscriptome sequencing, as well as metabolome characterisation. Despite being technically more challenging, whole-genome profiling and metabolomics can address the questions 'what can they do?' and 'what are they doing?' This review provides an overview of the basic principles of high-throughput microbiome sequencing techniques, current literature on sputum microbiome profiling in COPD, and a discussion of the associated limitations and future perspectives.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Ditz B, Christenson S, Rossen J, et al. Sputum microbiome profiling in COPD: beyond singular pathogen detection. Thorax. 2020. PMID: 31996401. doi:10.1136/thoraxjnl-2019-214168

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。